Gilead Sciences (NASDAQ:GILD) Given New $95.00 Price Target at Barclays
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective raised by Barclays from $84.00 to $95.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. Other research analysts have also issued research reports about the company. Sanford C. Bernstein started coverage on […]
More Stories
Mawson Gold Limited (OTCMKTS:MWSNF) Short Interest Update
Mawson Gold Limited (OTCMKTS:MWSNF – Get Free Report) was the recipient of a significant decline in short interest in the...
WaFd, Inc (NASDAQ:WAFD) Short Interest Up 26.8% in December
WaFd, Inc (NASDAQ:WAFD – Get Free Report) was the recipient of a large growth in short interest in the month...
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Sees Large Decline in Short Interest
Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) saw a significant decrease in short interest in December. As of December...
BlackRock Taxable Municipal Bond Trust (NYSE:BBN) Short Interest Up 52.8% in December
BlackRock Taxable Municipal Bond Trust (NYSE:BBN – Get Free Report) saw a significant increase in short interest during the month...
How QR Code Scanners Help The Restaurant Industry?
The hotel sector is hoping that contactless ordering would help it recover in the aftermath of the epidemic as the...
The Best Cybersecurity Books to Improve Your Skill
Knowing how cybersecurity operates is crucial in an era where cyberthreats are increasing in frequency. By having this knowledge, you...